Making One Health Better Biome for One Health
Making One Health Better Biome for One Health
Welcome ! We are V1bio Inc.
V1bio is a biotechnology company that was founded with the objective of creating a healthy and valuable one-health ecosystem and revolutionizing the lives of patients worldwide through innovative microbiome therapies. In pursuit of this goal, the company is actively engaged in the research and development of a range of immune and anti-cancer treatments as well as animal health nutrition products using one-health microbiomes. These treatments have the potential to significantly improve the lives of individuals and animals suffering from various diseases and conditions that affect the immune system. V1bio is committed to utilizing cutting-edge technology and research to develop groundbreaking treatments that have the power to transform the lives of patients globally.
Vision
Mission
Mission
' Top-tier microbiome biotechnology company '
We are dedicated to pursuing groundbreaking microbiome to discover and develop medicines
Mission
Mission
Mission
Our mission is to provide the better lives of patients worldwide with revolutionary One Health microbiome and solutions
Value
Mission
Value
Respect for people, Act with intergrity
Communication with open-minded
Continuous challenge for innovation
Pioneer in utilizing revolutionary microbe as medicine
Proprietary platform
Proprietary platform
Proprietary platform
One Health microbiome library
Microbiome profiling (AI & BI)
Multi-omics analysis, Translational research
Focus areas
Proprietary platform
Proprietary platform
Live biotherapeutic product
Oncology, Immunology
One Health microbiome (human, ainimal)
Open collaboration
Proprietary platform
Open collaboration
Collaborative research
In-Iicensing
Out-licensing
History
Growth 2023
2023. 05. V1bio-HK Komar Pet quasi-drugs MOU to co-operate on microbiome product
Growth 2022
2022. 10. V1bio-Daewoong Pet MOU to co-operate on microbiome product for companion dog
2022. 08. V1bio-Ahnkook pharm MOU to co-operate on microbiome R&D
2022. 08. Establishment of a research institute (wet-lab)
2022. 08. Selection of TIPA ValueUp program by Korea Technology and Information Promotion Agency for SMEs
2022. 04. Selection of youth employment intern system participating company by the Ministry of Employment and Labor
2022. 03. Selection of KIT family company by the Korea Insitute of Toxicology
2022. 02. Selection of 2022 TIPS program by the Ministry of SMEs and Startups
Begin 2021
2021. 12. Selection of K-STARTUP venture post-support program by the Ministry of SMEs and Startups
2021. 12. Certification of the company-affiliated research institute
2021. 11. Seed funding by the DAEWOONG Pharmaceuticals
2021. 11. Certification of the venture company
2021. 09. Seed funding by the Schmidt
2021. 05. Establishment of V1bio Inc
Network
Investor & Supporter
